"Differing from its predecessor, ENLIGHT has been designed and evaluated with two real-world clinical scenarios in mind: personalized oncology, where one matches the best treatment to a patient based on a fixed decision threshold, and CTD, where the goal is to a priori exclude non-responding patients in the best possible manner. "

#immunotherapy #Immunology #TumorImmunology #Biomarker #PersonalisedMedicine

https://www.cell.com/med/fulltext/S2666-6340(22)00455-X#secsectitle0105